Search This Blog

Wednesday, February 25, 2026

FDA accepts Viatris sNDA for MR-141 (phentolamine ophthalmic solution 0.75%) to treat presbyopia

 


  • FDA assigned a PDUFA target date of October 17, 2026 for the MR-141 presbyopia application.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)